Nath Bio-Genes (India) Ltd's Q3FY25 Quarterly Results

Result Summary

• Nath Bio-Genes (India) Ltd reported a 15.7% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 17.5%.
• Its expenses for the quarter were up by 7.6% QoQ and 13.0% YoY.
• The net profit increased 138.7% QoQ and decreased 30.8% YoY.
• The earnings per share (EPS) of Nath Bio-Genes (India) Ltd stood at 1.3 during Q3FY25.

Financial Statments for Q3FY25

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Nath Bio-Genes (India) Ltd is a prominent player in the agriculture sector, primarily focusing on the research, development, production, and marketing of hybrid and genetically modified seeds. The company's product portfolio includes a wide range of seeds for crops such as cotton, paddy, maize, and vegetables. As a key contributor to the agribusiness domain, Nath Bio-Genes plays a crucial role in improving crop yields and enhancing farmer productivity. While no specific recent major developments are available in the provided data, the company continues to operate within the dynamic agricultural biotechnology industry.

Revenue

During the third quarter of the fiscal year 2025 (Q3FY25), Nath Bio-Genes (India) Ltd reported a total income of ₹37.35 crores. This marks a quarter-over-quarter (QoQ) increase of 15.7% from the previous quarter (Q2FY25), where the total income was ₹32.27 crores. Additionally, there is a year-over-year (YoY) growth of 17.5% compared to Q3FY24, which recorded a total income of ₹31.78 crores. This upward trend in revenue indicates a consistent increase in the company's income over the observed periods.

Profitability

The profitability of Nath Bio-Genes (India) Ltd in Q3FY25 is characterized by a profit before tax (PBT) of ₹3.79 crores. This represents a significant QoQ growth of 247.7% from Q2FY25, which had a PBT of ₹1.09 crores. However, on a YoY basis, there was a decrease of 17.4% when compared to Q3FY24's PBT of ₹4.59 crores. The company incurred a tax expense of ₹1.14 crores in Q3FY25, a notable increase from the tax refund of ₹0.03 crores in Q2FY25, translating to a substantial QoQ swing. The profit after tax (PAT) for Q3FY25 stood at ₹2.65 crores, which is 138.7% higher than the previous quarter's PAT of ₹1.11 crores, but 30.8% lower than the PAT of ₹3.83 crores in Q3FY24.

Operating Metrics

The earnings per share (EPS) for Nath Bio-Genes (India) Ltd in Q3FY25 was ₹1.30, showing a QoQ increase of 160.0% from ₹0.50 in Q2FY25. However, this represents a YoY decline of 35.0% from the EPS of ₹2.00 in Q3FY24. Total expenses for the company in Q3FY25 amounted to ₹33.56 crores, reflecting a QoQ rise of 7.6% from ₹31.18 crores in the prior quarter and a YoY increase of 13.0% from ₹29.69 crores in Q3FY24. These figures indicate fluctuations in both income and expenses, contributing to the variations observed in profitability metrics for the period under review.